Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Taiwan ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while iShares MSCI Taiwan ETF trades at $103.7. The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | EWT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $111.53 |
52-Week Low | $20.06 | $57.66 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWT trades at $107.27, up 2.3% with strong bullish momentum from moving averages. The ETF has more than doubled in the past year, driven by Taiwan's semiconductor sector dominance and AI infrastructure demand. Technical indicators show neutral oscillators but overall buy signals dominate. Recent news highlights geopolitical tensions and semiconductor supply chain importance as key drivers.
Outlook remains positive given Taiwan's critical role in global tech supply chains, though stretched valuations and China-Taiwan geopolitical risks pose significant headwinds. The concentration in tech stocks like TSMC offers growth exposure but increases vulnerability to sector-specific downturns and trade disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
